Jun Oyanagi

624 total citations
24 papers, 475 citations indexed

About

Jun Oyanagi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Jun Oyanagi has authored 24 papers receiving a total of 475 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 7 papers in Cancer Research. Recurrent topics in Jun Oyanagi's work include Lung Cancer Treatments and Mutations (12 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Colorectal Cancer Treatments and Studies (4 papers). Jun Oyanagi is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Colorectal Cancer Treatments and Studies (4 papers). Jun Oyanagi collaborates with scholars based in Japan. Jun Oyanagi's co-authors include Kaoru Miyazaki, Takashi Ogawa, Shouichi Higashi, Yasuhiro Koh, Nobuyuki Yamamoto, Hiroki Sato, Yohei Miyagi, Hiromichi Kumagai, Shinsaku Togo and Daisuke Hoshino and has published in prestigious journals such as PLoS ONE, Cancer Research and Oncogene.

In The Last Decade

Jun Oyanagi

24 papers receiving 472 citations

Peers

Countries citing papers authored by Jun Oyanagi

Since Specialization

Citations

This map shows the geographic impact of Jun Oyanagi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jun Oyanagi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jun Oyanagi more than expected).

Fields of papers citing papers by Jun Oyanagi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jun Oyanagi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jun Oyanagi. The network helps show where Jun Oyanagi may publish in the future.

Co-authorship network of co-authors of Jun Oyanagi

This figure shows the co-authorship network connecting the top 25 collaborators of Jun Oyanagi. A scholar is included among the top collaborators of Jun Oyanagi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jun Oyanagi. Jun Oyanagi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial 2023 ·BMC Cancer ·Satoru Miura, Yasuhiro Koh, Koichi Azuma, Hiroshige Yoshioka, K. Koyama, Shunsuke Teraoka, Hidenobu Ishii, Kayoko Kibata, Yuichi Ozawa, Takaaki Tokito, Jun Oyanagi, Toshio Shimokawa, Takayasu Kurata, Nobuyuki Yamamoto, Hiroshi Tanaka	5
2	Nivolumab Retreatment in Non–Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L) 2022 ·Clinical Cancer Research ·Hiroaki Akamatsu, Shunsuke Teraoka, Shinkichi Takamori, Satoru Miura, Hidetoshi Hayashi, Akito Hata, Yukihiro Toi, Yoshimasa Shiraishi, Nobuaki Mamesaya, Yuki Sato, Naoki Furuya, Jun Oyanagi, Yasuhiro Koh, Toshihiro Misumi, Nobuyuki Yamamoto, Kazuhiko Nakagawa	22
3	Pre-treatment serum protein levels predict survival of non-small cell lung cancer patients without durable clinical benefit by PD-1/L1 inhibitors 2022 ·Cancer Immunology Immunotherapy ·(unknown), Yuichi Ozawa, Eriko Murakami, Koichi Sato, Jun Oyanagi, Hiroaki Akamatsu, (unknown), Ryota Shibaki, (unknown), (unknown), Shunsuke Teraoka, Nahomi Tokudome, Atsushi Hayata, Hiroki Ueda, Masanori Nakanishi, Yasuhiro Koh, Nobuyuki Yamamoto	7
4	Tumor microenvironment disparity in multiple primary lung cancers: Impact of non-intrinsic factors, histological subtypes, and genetic aberrations 2021 ·Translational Oncology ·(unknown), Kenji Sawa, Jun Oyanagi, (unknown), Mitsuru Fukui, (unknown), (unknown), (unknown), Tomohiro Suzumura, Tetsuya Watanabe, Hiroyasu Kaneda, Shigeki Mitsuoka, Kazuhisa Asai, Noritoshi Nishiyama, Masahiko Ohsawa, Nobuyuki Yamamoto, Yasuhiro Koh, Tomoya Kawaguchi	11
5	Phase Ib Study of Osimertinib Plus Ramucirumab in Japanese Lung Cancer Patients With EGFR Mutation 2021 ·Anticancer Research ·Hiroaki Akamatsu, Yuichi Ozawa, Jun Oyanagi, Daichi Fujimoto, Akito Hata, Nobuyuki Katakami, Keisuke Tomii, Eriko Murakami, (unknown), Toshio Shimokawa, Yasuhiro Koh, Nobuyuki Yamamoto	4
6	Bloodborne Cytokines for Predicting Clinical Benefits and Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated With Anti-Programmed Cell Death 1 Inhibitors 2021 ·Clinical Lung Cancer ·Jun Oyanagi, Yasuhiro Koh, Koichi Sato, Shunsuke Teraoka, Nahomi Tokudome, Atsushi Hayata, Hiroaki Akamatsu, Yuichi Ozawa, Masanori Nakanishi, Hiroki Ueda, Nobuyuki Yamamoto	4
7	High-purity Isolation for Genotyping Rare Cancer Cells from Blood Using a Microfluidic Chip Cell Sorter 2021 ·Anticancer Research ·Mio Ikeda, Yasuhiro Koh, Jun Oyanagi, Shunsuke Teraoka, (unknown), (unknown), Kazuo Takeda, Nahomi Tokudome, Yuichi Ozawa, Hiroki Ueda, Nobuyuki Yamamoto	3
8	Mutational landscape of multiple primary lung cancers and its correlation with non-intrinsic risk factors 2021 ·Scientific Reports ·(unknown), Jun Oyanagi, Kenji Sawa, Mitsuru Fukui, (unknown), (unknown), (unknown), Tomohiro Suzumura, Tetsuya Watanabe, Hiroyasu Kaneda, Shigeki Mitsuoka, Kazuhisa Asai, Masahiko Ohsawa, Nobuyuki Yamamoto, Yasuhiro Koh, Tomoya Kawaguchi	18
9	Hypoxia Inducible Factor-1α Inhibition in Von Hippel Lindau-mutant Malignant Pleural Mesothelioma Cells 2020 ·Anticancer Research ·Takehito Shukuya, Jun Oyanagi, Masakuni Serizawa, Masaru Watanabe, Nobuyuki Yamamoto, Yasuhiro Koh	4
10	Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab 2019 ·Lung Cancer ·Jun Oyanagi, Yasuhiro Koh, Koichi Sato, Keita Mori, Shunsuke Teraoka, Hiroaki Akamatsu, Kuninobu Kanai, Atsushi Hayata, Nahomi Tokudome, Keiichiro Akamatsu, Masanori Nakanishi, Hiroki Ueda, Nobuyuki Yamamoto	47
11	Impact of tumor microenvironment on the efficacy of epidermal growth factor receptor‐tyrosine kinase inhibitors in patients with EGFR‐mutant non‐small cell lung cancer 2019 ·Cancer Science ·(unknown), Kenji Sawa, Mitsuru Fukui, Jun Oyanagi, (unknown), (unknown), Tomohiro Suzumura, Tetsuya Watanabe, Hiroyasu Kaneda, Shigeki Mitsuoka, Kazuhisa Asai, Tatsuo Kimura, Nobuyuki Yamamoto, Yasuhiro Koh, Tomoya Kawaguchi	31
12	Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors 2019 ·Lung Cancer ·(unknown), Kenji Sawa, Mitsuru Fukui, Jun Oyanagi, Naoki Yoshimoto, Tomohiro Suzumura, Tetsuya Watanabe, Hiroyasu Kaneda, Shigeki Mitsuoka, Kazuhisa Asai, Tatsuo Kimura, Nobuyuki Yamamoto, Kazuto Hirata, Yasuhiro Koh, Tomoya Kawaguchi	9
13	Cancer cell migration on elongate protrusions of fibroblasts in collagen matrix 2019 ·Scientific Reports ·Kaoru Miyazaki, Jun Oyanagi, Daisuke Hoshino, Shinsaku Togo, Hiromichi Kumagai, Yohei Miyagi	70
14	Abstract 2613: Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors 2018 ·Cancer Research ·(unknown), Kenji Sawa, Jun Oyanagi, Mitsuru Fukui, Naoki Yoshimoto, Tomohiro Suzumura, Shigeki Mitsuoka, Kazuhisa Asai, Tatsuo Kimura, Nobuyuki Yamamoto, Tomoya Kawaguchi, Kazuto Hirata, Yasuhiro Koh	1
15	Suppression of intestinal tumors by targeting the mitotic spindle of intestinal stem cells 2016 ·Oncogene ·Ryoji Yao, Jun Oyanagi, Yasuko Natsume, (unknown), Yukio Kato, Satoshi Nagayama, T Noda	8
16	Inhibition of transforming growth factor-β signaling potentiates tumor cell invasion into collagen matrix induced by fibroblast-derived hepatocyte growth factor 2014 ·Experimental Cell Research ·Jun Oyanagi, (unknown), (unknown), Shouichi Higashi, Keiji Kikuchi, Katsuya Sakai, Kunio Matsumoto, Kaoru Miyazaki	29
17	Modulation of matrix metalloproteinase-9 secretion from tumor-associated macrophage-like cells by proteolytically processed laminin-332 (laminin-5) 2013 ·Clinical & Experimental Metastasis ·Go Kamoshida, Takashi Ogawa, Jun Oyanagi, Hiroki Sato, Eriko Komiya, Shouichi Higashi, Kaoru Miyazaki, Tsutomu Tsuji	10
18	Amino‐terminal fragments of laminin γ2 chain retract vascular endothelial cells and increase vascular permeability 2013 ·Cancer Science ·Hiroki Sato, Jun Oyanagi, Eriko Komiya, Takashi Ogawa, Shouichi Higashi, Kaoru Miyazaki	12
19	Epithelial-Mesenchymal Transition Stimulates Human Cancer Cells to Extend Microtubule-based Invasive Protrusions and Suppresses Cell Growth in Collagen Gel 2012 ·PLoS ONE ·Jun Oyanagi, Takashi Ogawa, Hiroki Sato, Shouichi Higashi, Kaoru Miyazaki	58
20	Expression of laminin γ2 chain monomer enhances invasive growth of human carcinoma cells in vivo 2010 ·International Journal of Cancer ·Yoshiaki Tsubota, Takashi Ogawa, Jun Oyanagi, Yoji Nagashima, Kaoru Miyazaki	23

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact